Beam Therapeutics (NASDAQ:BEAM) Trading 5.5% Higher on Analyst Upgrade

Beam Therapeutics Inc. (NASDAQ:BEAM)’s stock price was up 5.5% on Thursday after Citigroup raised their price target on the stock from $64.00 to $68.00. Citigroup currently has a buy rating on the stock. Beam Therapeutics traded as high as $24.46 and last traded at $24.3930. Approximately 513,977 shares traded hands during trading, a decline of 74% from the average daily volume of 1,944,699 shares. The stock had previously closed at $23.12.

A number of other research analysts also recently commented on the stock. Royal Bank Of Canada raised their target price on shares of Beam Therapeutics from $22.00 to $26.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 25th. UBS Group started coverage on shares of Beam Therapeutics in a research note on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. Sanford C. Bernstein lifted their price objective on shares of Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Wedbush boosted their price objective on shares of Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.87.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 18,629 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $34.61, for a total value of $644,749.69. Following the completion of the transaction, the insider directly owned 97,038 shares in the company, valued at approximately $3,358,485.18. The trade was a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.50% of the stock is owned by company insiders.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Updated Phase 1/2 efficacy: a single 60 mg dose produced mean steady‑state total AAT of 16.1 µM (above the protective 11 µM threshold), durable functional increases, ~84% reduction in toxic Z‑AAT and ~94% corrected M‑AAT composition — data the company says support a one‑time corrective therapy. Beam Therapeutics Announces Compelling Updated Clinical Data…
• Positive Sentiment: Company advanced program plans: Beam selected 60 mg as the optimal biological dose and intends to start a global pivotal cohort in H2 2026 pursuing an FDA accelerated‑approval path with ~50 additional patients. Beam Discusses Topline Phase I/II Data for BEAM-302…
• Positive Sentiment: Broad positive press and market reaction: multiple outlets reported the results and noted share gains after the update, reinforcing near‑term investor enthusiasm. Beam Therapeutics stock jumps on positive trial data
• Neutral Sentiment: Company hosted an investor webcast to review the dataset and next steps; replay and slides are available for investors seeking detail on endpoints and safety. Beam Discusses Topline Phase I/II Data for BEAM-302…
• Neutral Sentiment: Third‑party recaps (BiopharmaDive, Benzinga, Quiver) summarize the same data, dose choice and timelines — useful for context but largely echo the company release. Beam posts positive data on base editing treatment for AATD
• Negative Sentiment: Safety signals to monitor: while no serious AEs were reported in single‑dose cohorts, the multi‑dose cohort included Grade 4 ALT and Grade 3 AST elevations in one patient and other transient LFT elevations — these will be focal points for regulators and investors as the program advances. Beam Therapeutics Announces Compelling Updated Clinical Data…
• Negative Sentiment: Execution and regulatory risk remain: the pivotal cohort is expected H2 2026 but timelines, durability beyond follow‑up windows, manufacturing and long‑term safety are open risks that could affect valuation and approval timing. Beam to advance gene-editing drug to pivotal development
• Neutral Sentiment: Short‑interest data in feeds appears inconsistent/erroneous (reported as zero) and is not meaningful for reading current sentiment. Beam Therapeutics shares climb after positive BEAM-302 trial update

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its stake in Beam Therapeutics by 24.8% in the third quarter. ARK Investment Management LLC now owns 11,038,834 shares of the company’s stock valued at $267,913,000 after acquiring an additional 2,190,993 shares in the last quarter. Contrarius Group Holdings Ltd purchased a new stake in shares of Beam Therapeutics during the 3rd quarter valued at $37,212,000. MWG Caph Ltd purchased a new stake in shares of Beam Therapeutics during the 4th quarter valued at $35,119,000. State Street Corp boosted its position in shares of Beam Therapeutics by 30.4% in the 4th quarter. State Street Corp now owns 5,228,529 shares of the company’s stock worth $144,935,000 after purchasing an additional 1,219,871 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Beam Therapeutics by 237.5% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock worth $40,419,000 after purchasing an additional 1,171,977 shares in the last quarter. Institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Stock Performance

The company has a 50 day moving average of $27.79 and a two-hundred day moving average of $26.27. The stock has a market capitalization of $2.42 billion, a PE ratio of -23.56 and a beta of 2.12.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 24th. The company reported $2.33 EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. The company had revenue of $114.11 million during the quarter, compared to analysts’ expectations of $13.22 million. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The firm’s revenue was up 280.3% compared to the same quarter last year. During the same period last year, the business posted ($1.09) earnings per share. As a group, research analysts predict that Beam Therapeutics Inc. will post -4.57 EPS for the current fiscal year.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.